tradingkey.logo

BRIEF-Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial

ReutersFeb 18, 2025 2:55 PM

- Septerna Inc SEPN.O:

  • SEPTERNA ANNOUNCES DISCONTINUATION OF SEP-786 PHASE 1 CLINICAL TRIAL AND PLANS TO ADVANCE NEXT-GENERATION ORAL SMALL MOLECULE PTH1R AGONIST

  • SEPTERNA INC - DECISION FOLLOWS SEVERE EVENTS OF ELEVATED BILIRUBIN IN PHASE 1 TRIAL

  • SEPTERNA INC - NO LIVER INJURY OR SERIOUS ADVERSE EVENTS IN PHASE 1 TRIAL

  • SEPTERNA INC - EXPECTS CASH POSITION TO SUPPORT OPERATIONS INTO 2027

  • SEPTERNA INC: ADVANCING MULTIPLE NEXT-GENERATION PTH1R AGONISTS WITH DISTINCT AND UNRELATED CHEMICAL STRUCTURES RELATIVE TO SEP-786

Source text: ID:nGNXbKM318

Further company coverage: SEPN.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI